Zogenix Revenue and Competitors
Estimated Revenue & Valuation
- Zogenix's estimated annual revenue is currently $24.1M per year.
- Zogenix received $288.9M in venture funding in October 2017.
- Zogenix's estimated revenue per employee is $211,579
- Zogenix's total funding is $1.5B.
Employee Data
- Zogenix has 114 Employees.
- Zogenix grew their employee count by -9% last year.
Zogenix's People
| Name | Title | Email/Phone |
|---|---|---|
1 | V.P., Chemistry, Manufacturing, and Controls | Reveal Email/Phone |
2 | Head Regulatory Affairs, Europe | Reveal Email/Phone |
3 | Executive Director and Head Clinical Pharmacology | Reveal Email/Phone |
4 | Sr. Director Data Management | Reveal Email/Phone |
5 | Director, Manufacturing Operations | Reveal Email/Phone |
6 | Executive Director, Head Market Access and HE&OR | Reveal Email/Phone |
7 | Associate Director Program Management | Reveal Email/Phone |
8 | Senior Director, Small Molecule Process Development | Reveal Email/Phone |
9 | Medical director Zogenix France | Reveal Email/Phone |
10 | Sr Manager Pharmaceutical Packaging Operations Europe | Reveal Email/Phone |
Zogenix Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $84.8M | 422 | 24% | N/A | N/A |
#2 | $0.4M | 2 | 0% | N/A | N/A |
#3 | $32M | 159 | 3% | N/A | N/A |
#4 | $35M | 121 | 3% | $62.5M | N/A |
#5 | $30.2M | 150 | 18% | N/A | N/A |
#6 | $135.3M | 673 | 0% | N/A | N/A |
#7 | $110.3M | 549 | N/A | N/A | N/A |
#8 | $60.1M | 299 | -4% | N/A | N/A |
#9 | $554.8M | 1725 | 2% | N/A | N/A |
#10 | $10.5M | 52 | 4% | N/A | N/A |
What Is Zogenix?
Zogenix is committed to developing and commercializing therapies for central nervous system disorders that address specific clinical needs for people living with rare diseases and other CNS disorders who need innovative treatment alternatives to improve their daily functioning. We seek best-in-class leaders with scientific, medical and commercial expertise in the therapeutic areas in which we participate. By sharing a collective passion for making a difference in the lives of patients we serve, our unique company culture thrives through the principles of ethical decision making, open communication and collaboration.
keywords:Biotechnology,Healthcare,Pharmaceuticals
$1.5B
Total Funding
114
Number of Employees
$24.1M
Revenue (est)
-9%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Zogenix News
Northland Securities downgraded shares of Zogenix from an outperform rating to a market perform rating in a report on Monday, February 28th.
JMP Securities downgraded Zogenix from an outperform rating to a market perform rating in a research note on Wednesday, January 19th. Zacks...
Zogenix, Inc. (NASDAQ:ZGNX) Given Average Recommendation of Hold by Brokerages. Posted by admin on Apr 13th, 2022.
EMERYVILLE, Calif., Aug. 9, 2021 /PRNewswire/ -- Zogenix, a global biopharmaceutical company developing rare disease therapies, today announced it will donate $50,000 to be equally divided between the Dravet Syndrome Foundation and Epilepsy Foundation, in support of the work they do for patien ...
EMERYVILLE, Calif., Sept. 09, 2019 (GLOBE NEWSWIRE) -- Zogenix, Inc. (NASDAQ: ZGNX), a global pharmaceutical company developing ...
Other Companies in Emeryville
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $30.8M | 114 | 6% | N/A |
#2 | $18M | 116 | 1% | N/A |
#3 | $26.8M | 118 | 33% | N/A |
#4 | $18.8M | 121 | 64% | N/A |
#5 | $30.1M | 124 | -18% | N/A |
Zogenix Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2006-08-29 | $60.0M | A | Clarus Ventures, Domain Associates LLC | Article |
| 2006-09-28 | $60.0M | Undisclosed | Clarus Ventures, Domain Associates | Article |
| 2008-01-10 | $18.0M | Undisclosed | Abingworth Management Ltd | Article |
| 2008-07-29 | $18.0M | Undisclosed | Oxford Finance Corporation, CIT Healthcare LLC | Article |
| 2009-09-24 | $51.0M | Undisclosed | Clarus Ventures, Domain Associates | Article |
| 2009-12-08 | $35.0M | Undisclosed | Chicago Growth Partners, Clarus Ventures | Article |
| 2010-07-14 | $50.0M | Undisclosed | Oxford Finance Corporation | Article |
| 2011-09-19 | $69.0M | Undisclosed | Article | |
| 2012-07-25 | $60.7M | Undisclosed | Article | |
| 2013-11-05 | $60.0M | Undisclosed | Stifel | Article |
| 2013-11-14 | $64.4M | Undisclosed | Article | |
| 2015-07-31 | $98.3M | Undisclosed | Leerink Partners LLC | Article |
| 2017-10-04 | $288.9M | Undisclosed | Leerink Partners LLC | Article |